Revance Therapeutics Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH) announced an upward revision

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH ) announced an upward revision to its 2021 net revenue guidance from 30 million Danish Krone to 40 million Danish Krone ($4.6 million - $6.1 million) to 35 million Danish Krone to 37 million Danish Krone ($5.3 million-$5.6 million). The company also narrowed its operating loss outlook. The company noted that the improved financial outlook for 2021 is mainly driven by increased visibility on net revenues from the use of arimoclomol in the Early Access Program in France and lower-than-expected operating expenses due to strict cost management. The stock was surging up 7.66% to $ 2.39 in premarket trading. Galapagos'' Filgotinib Gets U.K. Regulatory Nod For Treating Ulcerative Colitis Galapagos NV (NASDAQ: GLPG ) announced that the Medicines and Healthcare products Regulatory Agency has granted a marketing authorization for Jyseleca (filgotinib 200mg tablets), as a new treatment for ulcerative colitis in Great Britain.

NEW YORK, Jan. 9, 2022 /PRNewswire/ --

NEW YORK, Dec. 23, 2021 /PRNewswire/ --

(PR-inside.com) BOSTON, MA / ACCESSWIRE / December 23, 2021 / The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Revance Therapeutics, Inc. (NASDAQ:RVNC). The case is currently in the lead plaintiff stage. Investors who purchased RVNC securities between November 25, 2019 and October 11, 2021 may contact the Thornton Law Firm''s investor protection team by visiting www.tenlaw.com/cases/Revance for more information. Investors may also email [email protected] or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/Revance The case alleges that Revance and its senior executives made misleading statements to investors and failed to disclose that: (i) quality ..

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Alfi, Inc. (NASDAQCM: ALF)

SAN FRANCISCO, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now .

Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-09585, is on behalf of a []

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (the Class Period) have until February 8, 2022, to seek appointment as lead plaintiff in Aramic LLC v. Revance Therapeutics, Inc. , No. 21-cv-09585. Commenced on December 10, 2021 in the Northern District of California, the Revance Therapeutics class action lawsuit charges Revance Therapeutics along with certain of its top executives with violations of the Securities Exchange Act of 1934.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 8, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (the “Class Period”). If you suffered a loss on your Revance investments or would like to inquire about potentia

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 21, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Revancesecurities between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm''s site: www.bgandg.com/rvnc. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange ..

Revance Therapeutics Inc. (NASDAQ:RVNC) shares, rose in value on Friday, 12/17/21, with the stock price up by 3.81% to the previous days close as strong demand from buyers drove the stock to $16.63. Actively observing the price movement in the last trading, the stock closed the session at $16.02, falling within a range of $15.50 A Bullish 2021 Outlook For Revance Therapeutics Inc. (NASDAQ: RVNC) Shares Read More »

Revance Therapeutics, Inc. (NASDAQ:RVNC) Director Angus C. Russell purchased 6,400 shares of Revance Therapeutics stock in a transaction dated Monday, December 13th. The stock was bought at an average cost of $15.74 per share, with a total value of $100,736.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which []